Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 15 versus DEXAMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 15 versus DEXAMPEX.
ADDERALL 15 vs DEXAMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Dextroamphetamine is a central nervous system stimulant that increases extracellular dopamine and norepinephrine levels by blocking their reuptake and promoting release from presynaptic terminals.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
5-10 mg orally once daily in the morning, maximum 20 mg/day.
None Documented
None Documented
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Terminal elimination half-life 10–13 hours in adults (7–8 hours in children). Longer in alkaline urine (up to 20 hours) due to reduced renal tubular reabsorption.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
Renal: ~90% as unchanged drug and metabolites (primarily deaminated metabolites); fecal/biliary <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant